Literature DB >> 8259246

Perfluoroperhydrophenanthrene (Vitreon) as a short-term vitreous substitute after complex vitreoretinal surgery.

T M Tanji1, G A Peyman, N J Mehta, C M Millsap.   

Abstract

Forty-one eyes underwent surgery for complex vitreoretinal disease, with perfluoroperhydrophenanthrene (Vitreon) used as an intraoperative tool and postoperative vitreous substitute. Postoperative use of Vitreon ranged from 3 days to 9 weeks (mean, 3.3 weeks). All retinas were reattached intraoperatively; 73% remained attached after the initial surgery. The final macular attachment rate was 100% after additional surgery. Four eyes that received a combination of Vitreon and silicone oil for simultaneous superior and inferior tamponade were successfully reattached after the initial procedure. Visual acuity improved or remained stable in 80% of the eyes. No toxic effects directly attributable to Vitreon were observed. Mean follow up was 9 months.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8259246

Source DB:  PubMed          Journal:  Ophthalmic Surg        ISSN: 0022-023X


  4 in total

1.  A pilot study on the use of silicone oil-RMN3 as heavier-than-water endotamponade agent.

Authors:  Stanislao Rizzo; Federica Genovesi-Ebert; Claudia Belting; Andrea Vento; Federica Cresti
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-06-28       Impact factor: 3.117

2.  Management of traumatic retinal detachment with vitreon in children.

Authors:  O Cekiç; C Batman; Y Totan; O Aslan; S Ozalp
Journal:  Int Ophthalmol       Date:  1999       Impact factor: 2.031

3.  The surgical management of retinopathy of prematurity using a perfluorocarbon liquid.

Authors:  C M Millsap; G A Peyman; P E Ma; M D Greve
Journal:  Int Ophthalmol       Date:  1994       Impact factor: 2.031

4.  The combined use of perfluorohexyloctane (F6H8) and silicone oil as an intraocular tamponade in the treatment of severe retinal detachment.

Authors:  Stanislao Rizzo; Federica Genovesi-Ebert; Claudia Belting
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-21       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.